Application of solifenacin for female overactive bladder failed in tolterodine treatment
10.3760/cma.j.issn.1000-6702.2011.11.018
- VernacularTitle:索利那新在托特罗定治疗失败的女性膀胱过度活动症中的应用效果
- Author:
Zhengsheng PAN
;
Dongya WANG
;
Weiqing QIAN
;
Zhongquan SUN
;
Zhengwang ZHANG
- Publication Type:Journal Article
- Keywords:
Urinary bladder,overactive;
Muscarinic antagonists;
Solifenacin;
Tolterodine;
Treatment outcome
- From:
Chinese Journal of Urology
2011;32(11):778-780
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the clinical efficacy and safety of solifenacin for female overactive bladder (OAB) who failed in toherodine treatment. MethodsFrom Jan 2010 to Oct 2010,48 cases of female OAB were treated with 5 mg/d solifenacin for 4 weeks after the failure of tolterodine treatment.The improvement of the perception of bladder condition as well as the mean numbers of day-time micturition,urgency episodes,urge incontinence episode per day,nocturia and pads usage were used as objective indexes for the evaluation of therapeutic effect. ResultsAfter 4-week solifenacin treatment,the mean numbers of day-time micturition,urgency episodes,urge incontinence episode per day,nocturia and pads usage were respectively decreased from the baselines ( 8.7 ± 1.5),(3.4 ± 2.1 ),( 2.4 ± 1.8 ),(2.1 ± 1.8 ) and (2.2 ±1.6) to be (7.2 ±2.5),(2.0 ±1.8),(1.5 ±1.2),(1.2 ±0.8) and (1.4 ±0.8).The perception of bladder condition was improved in 42 cases.The withdrawal from the treatment was seen in 3 cases due to headache and dry mouth.No severe adverse event was found in the rest 45 patients. Conclusion Solifenacin might be an effective and safe alternative agent in the treatment of female OAB who failed in tolterodine treatment.
